Brief: Scynexis Q3 EPS USD -0.06
06/11/2024 21:30
Nov 06 (Reuters) - Scynexis Q3 net income USD -2.808 million. * Q3 pretax profit USD -3.203 million * Q3 product revenue USD 660 thousand * Q3 operating expenses USD 10.98 million * Q3 basic EPS USD -0.06
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview